Compare Nuwellis Inc (NUWE) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Charles Schwab Corporation Common Stock — how do they compare? Nuwellis Inc trades at $0.8 (market cap $2.54M), while Charles Schwab Corporation Common Stock trades at $106.54 (market cap $184.24B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 72535.4× Nuwellis Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.2% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| NUWE | SCHW | |
|---|---|---|
Market Cap | $2.54M | $184.24B |
Sector | Technology | Financials |
52-Week High | $164.50 | $113.65 |
52-Week Low | $0.73 | $85.35 |
Enterprise Value | -$1.17M | — |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.7878, up 0.88% today, but remains in a bearish technical trend. The company shows strong gross margins of 69.69% and double-digit revenue growth, but faces significant profitability challenges with negative net income margins and ROE. Recent developments include a reverse stock split, new CEO appointment, and strategic partnerships expanding pediatric care footprint.
While NUWE demonstrates operational progress with revenue growth and margin improvement, persistent losses and negative cash flow present substantial risk. The mixed analyst sentiment and bearish technical indicators suggest cautious approach. Investment appeal hinges on successful execution of financial efficiency strategy and path to profitability.
Charles Schwab (SCHW) trades at $106.87, down 2.21% with a bearish technical signal. The stock shows strong fundamentals with Q2 2026 EPS beating expectations at $1.62 vs. $1.56 expected, continuing a trend of earnings beats. Revenue grew to $23.92B in 2025 with a robust 38.79% net income margin. Analyst consensus is bullish with 57% buy ratings and a $122.14 price target, representing 14% upside potential.
SCHW presents a compelling investment case with strong earnings momentum and expanding digital asset offerings, though near-term technical weakness and competitive pressures in the RIA custody space warrant caution. The company's diversified revenue streams and improving cash flow trends support long-term growth prospects despite current market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
